The full content of Annals is available to subscribers

Subscribe/Learn More  >
In the Clinic |

Clostridium difficile Infection

Margaret Trexler Hessen, MD
Ann Intern Med. 2010;153(7):ITC4-1. doi:10.7326/0003-4819-153-7-201010050-01004
Text Size: A A A

Antibiotic-associated diarrhea was described in the 1950s. By 1978, Clostridium difficile had been established as the most common cause of infection, accounting for 15% to 25% of cases (1). The reported incidence and severity as measured by total mortality and colectomy rates rose steadily from 1993 to 2003 (2). A national survey in 2008 of 648 U.S. hospitals reported an overall C. difficile prevalence of 13.1 per 1000 inpatients (3). In the past decade, a strain with increased virulence has been described in relation to outbreaks in Canada, the United States, and Europe. This strain, designated NAP1/BI/027, produces a binary toxin not previously associated with C. difficile and produces substantially (15- to 20-fold) more toxin A and B than other strains. This strain is associated with more severe disease and mortality rates of 7% or more. It also seems to be more readily transmissible, and has been associated with community-acquired disease in persons with no established risk factors, including peripartum women and children. It is very resistant to fluoroquinolones, and emergence is believed to have been fostered by extensive use of these drugs in health care settings and in the community (4–6). This emergence of a hypervirulent form of C. difficile should prompt increased caution in prescribing fluoroquinolones in addition to those agents previously identified as frequent triggers of C. difficile diarrhea.

First Page Preview

View Large
First page PDF preview


Grahic Jump Location

Treatment strategies for Clostridium difficile diarrhea. GI = gastrointestinal; ID = infectious disease; IV = intravenous; PO = oral; QID = four times daily; TID = three times daily.

*Leukocyte count ≥ 15 × 109 cells/L or creatinine level ≥ 1.5 times baseline.

†Associated with significant ileus, toxic megacolon, hypertension, or shock.

Grahic Jump Location




CME Activities are only available to ACP members and Individual Annals subscribers. If you are a member or a subscriber please sign in. Otherwise please become a member or subscribe to Annals.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $32.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.